Last reviewed · How we verify
Ketamine 0.5
Ketamine 0.5, developed by Balikesir University, is a marketed drug with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but it benefits from a strong patent protection until 2028, which may provide a competitive edge. However, the lack of detailed revenue data and key trial results poses a significant risk in assessing its commercial viability and therapeutic efficacy.
At a glance
| Generic name | Ketamine 0.5 |
|---|---|
| Also known as | Group 1 |
| Sponsor | Balikesir University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Pain Reduction for Limb Injuries in Pediatric Emergency Departments: Intranasal Fentanyl or Intranasal Ketamine vs Oral Morphine (PHASE3)
- Management of Pain in Lumbar Arthrodesis (PHASE4)
- Investigation of the NMDA Antagonist Ketamine as a Treatment for Tinnitus (PHASE2)
- Ketamine for Pain, Opioid Use, and Mental Health in Orthopedic Trauma Patients (PHASE4)
- Understanding the Role of the Kappa Opioid Receptor in Ketamine's Attenuation of Suicidal Thoughts (PHASE4)
- Erector Spinae Block Vs Ketamine-based Multimodal Analgesia Protocol in Lumber Decompressive Surgery (NA)
- Ketamine for Veterans With Parkinson's Disease (PHASE2)
- Ketamine Treatment of Youth Suicide Attempters (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |